On the basis of its robust tumour growth properties, in vivo SSTR2 expression and response to LuTate PRRT, the AR42J line was then used to explore the ability of a PARP inhibitor to potentiate the effects of LuTate treatment in vitro and in vivo. Here, SSTR2 is linked to neoplasm.